Literature DB >> 15927674

Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells.

Philipp Saiko1, Zsuzsanna Horvath, Christoph Illmer, Sibylle Madlener, Wolfgang Bauer, Thomas Hoechtl, Natascha Erlach, Michael Grusch, Georg Krupitza, Robert M Mader, Walter Jaeger, Herbert Schott, Ram P Agarwal, Monika Fritzer-Szekeres, Thomas Szekeres.   

Abstract

Various amphiphilic heterodinucleoside phosphates have recently been synthesized in order to overcome drug resistance. These agents contain 5-fluorodeoxyuridine (5-FdUrd) and arabinofuranosylcytosine (Ara-C). We now investigated the action of two of these novel dimers (#2 and #10) in sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells. The dimers were compared with 5-FdUrd and Ara-C for growth inhibition, apoptosis induction, and cell-cycle effects. No significant difference in the cytotoxicity of dimer #2 could be observed between sensitive and 5-FdUrd/Ara-C cross-resistant H9 cells (IC50 values of 220 nM and 200 nM, respectively), indicating that further studies with this compound are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927674     DOI: 10.1016/j.leukres.2004.12.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.

Authors:  Jürgen Weinreich; Sarah Schott; Ingmar Königsrainer; Derek Zieker; Alfred Königsrainer; Herbert Schott
Journal:  Invest New Drugs       Date:  2010-07-02       Impact factor: 3.850

2.  Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Authors:  Irene V Bijnsdorp; Reto A Schwendener; Herbert Schott; Iduna Fichtner; Kees Smid; Adrie C Laan; Sarah Schott; Nienke Losekoot; Richard J Honeywell; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2009-12-03       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.